DHA douses fears of ‘ordained’ contractor in biometrics tender ructions

Home affairs minister Aaron Motsoaledi.

Home affairs minister Aaron Motsoaledi.

The Department of Home Affairs (DHA) has allayed fears that the Automated Biometric Identification System (ABIS) project has been ceded to an EOH subcontractor amid growing ructions over the contract.

Home affairs minister Aaron Motsoaledi yesterday fired a broadside to insinuations that French multinational technology company IDEMIA is the preferred company to take over the project from EOH.

The ABIS project is meant to migrate data on the current Home Affairs National Identification System, which only records photos and fingerprints of South African citizens, to the new ABIS system, but is behind schedule by more than two years.

The final implementation of the system would provide a single source of identification for citizens across state institutions and private-sector entities.

Implementation of the ABIS system was delayed after the missing of master files in the ABIS contract with EOH, and a forensic audit is under

Read More

N.J.’s medical marijuana chief douses senator’s pipe dream of legal weed for sale immediately after the election

EDITOR’S NOTE: NJ Cannabis Insider produces exclusive weekly content and monthly events geared toward those interested in the marijuana and hemp industries. To subscribe, visit njcannabisinsider.biz.

Not long after state Sen. Nick Scutari claimed on Tuesday legislators and regulators may “be able to flip the switch and people might be able to get marijuana, legally, right after the vote,” the head of the state medical cannabis program doused that pipe dream with a bucket of cold water.

“(Some dispensaries) literally do not even have the space to accommodate the level of demand that personal-use sales would bring,” said Jeff Brown, who helms the Department of Health’s Medicinal Marijuana Program. “I could say unequivocally that opening up sales even a few months after the election would be a disaster and would really hurt access for patients who need this as medicine. My number one priority is to ensure that the

Read More